“Combat Medical, a UK-based medical device innovator specializing in hyperthermic chemotherapy delivery, has secured £2.6 million in the first close of its Series A round. Led by the T&J Meyer Family Foundation and supported by Varia Ventures, NW Angel Fund, and various non-institutional investors, the capital will fuel the ongoing pivotal HIVEC HEAT Phase 3 trial. This FDA registration study targets BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), aiming to establish hyperthermic intravesical chemotherapy (HIVEC) as a bladder-preserving alternative to radical cystectomy for patients facing limited options.”
HIVEC HEAT Trial Advances with Fresh Capital as Unmet Needs Persist in Bladder Cancer Care
The recent £2.6 million Series A financing marks a significant milestone for Combat Medical, enabling accelerated progress in its mission to transform outcomes for patients with BCG-unresponsive non-muscle-invasive bladder cancer. This patient population represents a challenging subset of NMIBC cases, where standard Bacillus Calmette-Guérin (BCG) immunotherapy fails to control the disease. For these individuals, options often narrow to radical cystectomy—a major surgery involving bladder removal that carries substantial risks, impacts quality of life profoundly, and is not suitable for all patients due to comorbidities or personal preferences.
Combat Medical’s core technology revolves around its proprietary HIVEC system, which delivers hyperthermic intravesical chemotherapy. By recirculating heated chemotherapy—typically mitomycin C—directly into the bladder, the approach enhances drug penetration and efficacy compared to standard room-temperature instillations. Hyperthermia sensitizes cancer cells, increases chemotherapy uptake, and improves overall tumor-killing potential while maintaining a minimally invasive, outpatient-compatible profile.
The HIVEC HEAT trial stands as the centerpiece of this funding deployment. As a pivotal Phase 3 study, it is designed to generate robust evidence on the safety and effectiveness of HIVEC in BCG-unresponsive NMIBC. The trial focuses on key endpoints such as complete response rates, duration of response, progression-free survival, and avoidance of cystectomy. Success here could pave the way for FDA registration, positioning HIVEC as a potential new standard in bladder preservation for this high-risk group.
Bladder cancer remains one of the more common malignancies in the United States, with NMIBC comprising the majority of diagnoses. High-risk NMIBC patients often receive BCG as first-line intravesical therapy following transurethral resection. However, BCG unresponsiveness develops in a substantial portion—up to 40% in some high-risk cohorts—leading to recurrent or progressive disease. Current alternatives include other intravesical agents like gemcitabine/docetaxel combinations, gene therapies, or immune checkpoint inhibitors such as pembrolizumab for carcinoma in situ (CIS) cases. Despite these advances, many patients still face cystectomy as the definitive intervention, underscoring the urgent demand for effective, less invasive therapies.
Combat Medical’s approach builds on established principles of hyperthermia in oncology, adapted specifically for intravesical use. The recirculation mechanism ensures uniform temperature distribution and consistent drug exposure across the bladder lining, addressing limitations of passive instillation methods. Early clinical experience with HIVEC has demonstrated favorable tolerability, with side effects comparable to standard chemotherapy instillations and no added systemic toxicity risks from the heating component.
This funding round reflects growing investor confidence in medtech solutions targeting oncology unmet needs, particularly in urologic cancers where innovation has lagged behind other areas. The participation of family foundations and angel groups highlights the blend of strategic and philanthropic capital driving early-stage advancements in this space.
Looking at the broader landscape, the BCG-unresponsive segment has seen increased regulatory activity in recent years, with approvals expanding the toolkit available to urologists. Yet challenges persist around treatment durability, patient selection, sequencing of therapies, and access in community settings. A successful HIVEC HEAT outcome could complement existing options, offering a chemotherapy-based, device-enabled pathway that avoids systemic immunotherapy side effects or more invasive procedures.
The capital infusion will primarily support trial enrollment, site expansion, data monitoring, and preparatory steps for regulatory submission. Combat Medical’s global footprint—already spanning over 40 countries for its hyperthermic platforms—positions it well to scale if the trial meets its objectives, potentially bringing the technology to U.S. patients pending clearance.
For patients and clinicians grappling with BCG failure, this development signals meaningful momentum toward bladder-sparing strategies grounded in rigorous Phase 3 data. As the HIVEC HEAT trial progresses, it holds promise for shifting the treatment paradigm in one of the most recurrent and burdensome urologic cancers.
Disclaimer: This is a news report based on publicly available information. It is not investment, medical, or legal advice. Readers should consult qualified professionals for personalized guidance.